BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32382082)

  • 1. High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
    Hehlmann R; Voskanyan A; Lauseker M; Pfirrmann M; Kalmanti L; Rinaldetti S; Kohlbrenner K; Haferlach C; Schlegelberger B; Fabarius A; Seifarth W; Spieß B; Wuchter P; Krause S; Kolb HJ; Neubauer A; Hossfeld DK; Nerl C; Gratwohl A; Baerlocher GM; Burchert A; Brümmendorf TH; Hasford J; Hochhaus A; Saußele S; Baccarani M;
    Leukemia; 2020 Aug; 34(8):2074-2086. PubMed ID: 32382082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells].
    Dong XY; Li YL; Wu CY; Shang BJ; Zhang L; Cheng W; Zhu ZM
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):660-665. PubMed ID: 34547872
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
    Wang W; Tang G; Cortes JE; Liu H; Ai D; Yin CC; Li S; Khoury JD; Bueso-Ramos C; Medeiros LJ; Hu S
    J Hematol Oncol; 2015 Apr; 8():32. PubMed ID: 25888368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan.
    Tien HF; Chuang SM; Wang CH; Lee FY; Chien SH; Chen YC; Shen MC; Liu CH
    Cancer Genet Cytogenet; 1989 May; 39(1):89-97. PubMed ID: 2731152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
    Liu YL; Wang XN; Liu HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y; Wahner AE; Nguyen PL
    Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic findings in patients with acute promyelocytic leukemia and a case of CML blast crisis with promyelocytic proliferation.
    Kadam PR; Merchant AA; Advani SH
    Cancer Genet Cytogenet; 1990 Nov; 50(1):109-17. PubMed ID: 2253178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The morphological, immunophenotypical and cytogenetic characteristics study of blast crisis in chronic myeloid leukemia].
    Tang X; Wu D; Xue Y; Zhu M; Lu D; Ruan C
    Zhonghua Nei Ke Za Zhi; 2002 Oct; 41(10):685-7. PubMed ID: 12485536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia].
    Jonte F; Fernández-Fuertes F; Cecchini C; Luño E; Ordóñez A; Fernández C; Suárez P; Lausín A; Fernández J
    Sangre (Barc); 1992 Oct; 37(5):351-4. PubMed ID: 1293774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philadelphia chromosome negative acute lymphoblastic leukemia preceding Philadelphia positive chronic myelogenous leukemia.
    Hörnsten P; Nordenson I; Wahlin A
    Cancer Genet Cytogenet; 1989 Jun; 39(2):147-52. PubMed ID: 2752368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
    Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
    Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
    Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
    J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population.
    Morales-Chacón K; Bourlon C; Acosta-Medina AA; Bourlon MT; Aguayo A; Tuna-Aguilar E
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e299-e306. PubMed ID: 30905538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.